According to WHO, the concentrations of polysorbate 80 and aluminium found in neonatal Vitamin K injections remain well within globally accepted pharmacological safety margins. These compounds stabilise the formulation without toxicological risk, while the active vitamin K component prevents haemorrhagic disease of the newborn, reducing morbidity and mortality in early infancy